AMSBIO announces an extended and updated edition of its popular Organoid Culture Handbook.

Launched at the EMBO Symposium on Organoids: Modelling Organ Development and Disease in 3D Culture, the new 24-page handbook includes valuable information about the latest available products, protocols, example results and research paper citations.

Within the protocols section detailed information is provided on a general submerged method for organoid culture, crypt organoid culture techniques, the Air Liquid Interface (ALI) method for organoid culture and preparing clonal cultures from Igr5+ cells. 

 An extensive range of organoid culture examples are shown for organs including Liver (human, mouse and hepatocellular carcinoma), Gastrointestinal (small intestine, human colorectal, mouse and transgenic mouse), Esophageal (normal, cancerous, Barrett’s epithelial), Breast and Prostate. 

The handbook includes 8 recent peer review paper citations from leading international research laboratories using AMSBIO products for organoid culture.   

Organoids are organ-like structures that can be formed by 3D cell culture and differentiation of stem cells or organ progenitors. Organoids have been proven capable of recreating aspects of organ structure and function in vivo. As a consequence adoption of organoid culture models has now become widespread in areas including organogenesis models, drug testing, tumour / disease / infection models, toxicity screening, personalised medicine and regenerative medicine / organ replacement. 

AMSBIO offers a wide range of matrices and other solutions for 3D cell culture include natural hydrogels, recombinant matrices, artificial scaffolds and scaffold-free supports. Matrices from AMSBIO not only support cells and cell layers, but also play an essential role in tissue organization that affects cell adhesion, migration, proliferation, and differentiation. These aspects can be studied with tools from AMSBIO and the company’s experience in developing specialist matrices includes regulatory friendly solutions for regenerative medicine applications where customers are already in clinical trials. 

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO is able to draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective.

more about AMSBIO

more news from AMSBIO